U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287137) titled 'Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study' on Nov. 18.
Brief Summary: CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Study Start Date: Nov. 12
Study Type: INTERVENTIONAL
Condition:
COVID -19
COVID - 19
COVID 19
Influenza
Respiratory Virus
Respiratory Viruses
Respiratory Virus Infection
Respiratory Virus Infections
Intervention:
DRUG: Pfizer...